A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer
Status:
RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to compare efficacy and safety of DB-1303/BNT323 versus T-DM1 in HER2-positive, unresectable and/or metastatic breast cancer patients previously treated with trastuzumab and taxane.